Today: 9 June 2026
Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares
5 February 2026
2 mins read

Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares

New York, Feb 5, 2026, 14:04 EST — Regular session

  • Coupang shares slid roughly 9.7% in afternoon trading, hovering close to their lowest point of the day
  • Company says another 165,000 users were affected by the November leak but insists no payment or login details were compromised
  • The U.S. House panel has issued a subpoena to Coupang, while Bernstein initiates coverage with an Underperform rating.

Shares of Coupang Inc tumbled almost 10% Thursday, weighed down by a fresh cybersecurity alert from South Korea alongside a U.S. congressional subpoena deepening the company’s legal troubles. The stock fell 9.7% to $17.57 by 2:04 p.m. EST, sliding to as low as $17.53.

Timing is critical. Coupang’s Korean operations have been under a microscope ever since last year’s breach sparked political backlash in Seoul, complicating matters for U.S. investors eager for details on potential costs, penalties, and the company’s next steps.

Coupang revealed Thursday that data for another 165,000 users was exposed in the same breach reported last November. The leaked information includes names, phone numbers, and addresses, but payment details and login credentials were not affected. The company said users have been alerted following government protocols. This latest breach comes after a massive leak last year that hit over 33 million customers. A South Korean presidential adviser warned the incident is straining relations with Washington.

In Washington, the House Judiciary Committee subpoenaed Coupang amid its investigation into alleged discrimination against U.S. companies. The committee demands communications between Coupang and the South Korean government and has requested the company’s testimony. Coupang responded with a statement saying it will “fully cooperate,” including providing documents and witness testimony. Reuters

Bernstein jumped in with an Underperform rating on Coupang, setting a $17 price target, The Fly reported. On Wall Street, Underperform means the stock is forecasted to trail its peers over the long haul.

The selloff underscores how fast cybersecurity news can hit valuations. For a consumer platform, the threat extends beyond just remediation costs—it includes prolonged churn, increased scrutiny, and sluggish decision-making as investigations drag on.

Law firms ramped up public notices linked to the data breach fallout. Levi & Korsinsky issued a release highlighting a Feb. 17 deadline to file as lead plaintiff in a securities lawsuit, accusing the company of poor cybersecurity controls and delayed disclosure. (A lead plaintiff is the investor the court appoints to represent the entire class.)

Coupang confirmed the latest leak didn’t involve payment details or login credentials. That cuts down the immediate risk of fraud, though it doesn’t clear up the wider questions about ongoing investigations and possible fines.

If investigators determine the leak is contained and regulators hold back on penalties, the shares might find some relief. But if the situation worsens, expect more disclosures, stricter enforcement in South Korea, and growing litigation in the U.S., keeping the stock stuck under a shadow of negative headlines.

Traders have their eyes on South Korea as police prepare to summon Coupang Korea’s acting head, Harold Rogers, on Feb. 6 for questioning over alleged perjury tied to a National Assembly hearing, according to local media. Meanwhile, any move from the U.S. House panel on scheduling testimony or document requests could come swiftly.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters
Previous Story

Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters

Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away
Next Story

Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away

Go toTop